Théo Accogli
Research Subjects
Research Interests
Théo Accogli has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Bernard
Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France
5 shared publications - Caroline Truntzer
Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team
5 shared publications - Christophe Hibos
University of Burgundy, Dijon, France
5 shared publications - Corentin Richard
Georges-François Leclerc Cancer Center 1 Université Bourgogne Europe UNICANCER, Unit of Molecular Biology, Department of Biology and Pathology of Cancer, ICMUB UMR CNRS 6302, Dijon, France
5 shared publications - Emeric Limagne
Université Bourgogne Europe, INSERM, Center for Translational and Molecular Medicine, Institut Agro Dijon, UMR1231, Dijon, France
5 shared publications - Etienne Humblin
Marc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, NY, NY, USA
5 shared publications
Latest Publications
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification des fonctions non-canoniques de NLRP3 dans les Th17 - Intérêts thérapeutiques pour promouvoir la réponse immunitaire anti-tumorale
Depuis plusieurs décennies les cancers sont devenus un enjeu majeur de santé publique et occupent aujourd'hui la première place des causes de mortalité prématurée en France. L'une des caractéristiques des cellules cancéreuses est leur capacité à échapper au système immunitaire, notamment par la mise en place d'un environnement immunosuppresseur dans la tumeur. NLRP3 est une protéine étudiée principalement dans le contexte de l'inflammasome qu'elle forme afin de promouvoir l'inflammation principalement via la sécrétion d'IL-1β. Mais elle possède également des fonctions de facteur de transcription dans les lymphocytes T CD4+. Plus particulièrement dans les Th2, dont la fonction nécessite l'activité transcriptionnelle d'NLRP3, en coopération avec IRF4 qui forment ensemble un complexe capable d'augmenter l'expression de l'IL-4, l'IL-5 et l'IL-13 dans ces cellules.Ce travail porte sur les lymphocytes Th17, une population de lymphocytes T auxiliaires dont il existe plusieurs sous-types aux fonctions différentes. Parmi ces sous-types, deux s'opposent dans le contexte du cancer, les Th17 inflammatoires (Th17i) qui ont des propriétés anti-tumorales et les Th17 régulateurs (Th17r) qui ont des propriétés pro-tumorales.Le travail réalisé durant cette thèse a permis de mettre en évidence que la protéine NLRP3 participe à la balance entre Th17i et Th17r. En effet la déficience en NLRP3 limite l'apparition d'un profile Th17r au profit d'un phénotype plus proche des Th17i avec une augmentation de l'expression de cytokines pro-inflammatoires caractéristiques des Th17i telles que l'IFNγ, le GM-CSF ou l'IL-21. Cela confère à ces Th17r une activité activatrice des CD8+ qui sécrètent des quantités plus importantes d'IFNγ et de Granzyme B. Bien que l'interaction NLRP3/IRF4 existe dans le noyau des Th17r, c'est une autre fonction de NLRP3 qui module l'expression des gènes responsables de cette modification phénotypique. En effet, NLRP3 participe à la répression de gènes clés du programme transcriptionnel des Th17i, notamment en favorisant la phosphorylation de SMAD3. Ces éléments se traduisent par une activité anti-tumorale des cellules permettant de ralentir in vivo le développement tumoral. Ainsi, les infiltrats immunitaires observés dans les souris CD4crexNLRP3flox porteuses de tumeurs B16F10 et LLC1 en modèles sous-cutanées comme après un transfert adoptif de Th17rOT-II NLRP3-/- chez des souris porteuses de tumeurs B16F10OVA sont caractérisés par un infiltrat plus important en lymphocytes T CD8 dont les capacités cytotoxiques sont accrues et une diminution de l'infiltrat en Treg, entraînant une diminution de l'immunosuppression au sein de la tumeur.Ce travail a donc permis d'identifier NLRP3 comme un facteur clé de la polarisation Th17r, et a mis en lumière son rôle dans l'acquisition des fonctions immunosuppressives de cette sous-population de Th17.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification des fonctions non-canoniques de NLRP3 dans les Th17 - Intérêts thérapeutiques pour promouvoir la réponse immunitaire anti-tumorale
Depuis plusieurs décennies les cancers sont devenus un enjeu majeur de santé publique et occupent aujourd'hui la première place des causes de mortalité prématurée en France. L'une des caractéristiques des cellules cancéreuses est leur capacité à échapper au système immunitaire, notamment par la mise en place d'un environnement immunosuppresseur dans la tumeur. NLRP3 est une protéine étudiée principalement dans le contexte de l'inflammasome qu'elle forme afin de promouvoir l'inflammation principalement via la sécrétion d'IL-1β. Mais elle possède également des fonctions de facteur de transcription dans les lymphocytes T CD4+. Plus particulièrement dans les Th2, dont la fonction nécessite l'activité transcriptionnelle d'NLRP3, en coopération avec IRF4 qui forment ensemble un complexe capable d'augmenter l'expression de l'IL-4, l'IL-5 et l'IL-13 dans ces cellules.Ce travail porte sur les lymphocytes Th17, une population de lymphocytes T auxiliaires dont il existe plusieurs sous-types aux fonctions différentes. Parmi ces sous-types, deux s'opposent dans le contexte du cancer, les Th17 inflammatoires (Th17i) qui ont des propriétés anti-tumorales et les Th17 régulateurs (Th17r) qui ont des propriétés pro-tumorales.Le travail réalisé durant cette thèse a permis de mettre en évidence que la protéine NLRP3 participe à la balance entre Th17i et Th17r. En effet la déficience en NLRP3 limite l'apparition d'un profile Th17r au profit d'un phénotype plus proche des Th17i avec une augmentation de l'expression de cytokines pro-inflammatoires caractéristiques des Th17i telles que l'IFNγ, le GM-CSF ou l'IL-21. Cela confère à ces Th17r une activité activatrice des CD8+ qui sécrètent des quantités plus importantes d'IFNγ et de Granzyme B. Bien que l'interaction NLRP3/IRF4 existe dans le noyau des Th17r, c'est une autre fonction de NLRP3 qui module l'expression des gènes responsables de cette modification phénotypique. En effet, NLRP3 participe à la répression de gènes clés du programme transcriptionnel des Th17i, notamment en favorisant la phosphorylation de SMAD3. Ces éléments se traduisent par une activité anti-tumorale des cellules permettant de ralentir in vivo le développement tumoral. Ainsi, les infiltrats immunitaires observés dans les souris CD4crexNLRP3flox porteuses de tumeurs B16F10 et LLC1 en modèles sous-cutanées comme après un transfert adoptif de Th17rOT-II NLRP3-/- chez des souris porteuses de tumeurs B16F10OVA sont caractérisés par un infiltrat plus important en lymphocytes T CD8 dont les capacités cytotoxiques sont accrues et une diminution de l'infiltrat en Treg, entraînant une diminution de l'immunosuppression au sein de la tumeur.Ce travail a donc permis d'identifier NLRP3 comme un facteur clé de la polarisation Th17r, et a mis en lumière son rôle dans l'acquisition des fonctions immunosuppressives de cette sous-population de Th17.
- Open Access
- 6 July 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (7) , 1700-1709
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. We show that long-lived CAR-T cells developed a CD4/CD8 double-negative phenotype with an exhausted-like memory state and distinct transcriptional signature. This persistence signature was dominant among circulating CAR-T cells in all children with a long-lived treatment response for which sequencing data were sufficient (4/4, 100%). The signature was also present across T cell subsets and clonotypes, indicating that persisting CAR-T cells converge transcriptionally. This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. Examination of single T cell transcriptomes from a wide range of healthy and diseased tissues across children and adults indicated that the persistence signature may be specific to long-lived CAR-T cells. These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists.
- 6 July 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (7) , 1700-1709
Open AccessTranscriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. We show that long-lived CAR-T cells developed a CD4/CD8 double-negative phenotype with an exhausted-like memory state and distinct transcriptional signature. This persistence signature was dominant among circulating CAR-T cells in all children with a long-lived treatment response for which sequencing data were sufficient (4/4, 100%). The signature was also present across T cell subsets and clonotypes, indicating that persisting CAR-T cells converge transcriptionally. This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. Examination of single T cell transcriptomes from a wide range of healthy and diseased tissues across children and adults indicated that the persistence signature may be specific to long-lived CAR-T cells. These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.